Zhejiang Hisun Pharmaceutical has been granted a patent for indazole derivatives as IRAK4 inhibitors. The compounds of formula (I) are provided along with their preparation method and therapeutic use. GlobalData’s report on Zhejiang Hisun Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zhejiang Hisun Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Zhejiang Hisun Pharmaceutical's grant share as of April 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11897863B2) discloses a compound of formula (I) and its various forms, including stereoisomers, tautomers, and pharmaceutically acceptable salts. The patent also covers the compound's structures of formula (III), (IV), (Va), (Vb), and (Vc), along with pharmaceutical compositions containing these compounds and optional carriers. Furthermore, the patent claims methods for inhibiting IRAK4 kinase activity and preventing or treating autoimmune diseases, inflammatory diseases, or cancers by administering the disclosed compounds to subjects in need.
Specifically, the patent outlines the use of the compound to inhibit IRAK4 kinase activity, which is crucial in addressing autoimmune diseases, inflammatory diseases, and cancers. The methods described in the patent involve administering the compound or pharmaceutical compositions containing it to individuals requiring treatment. The patent also specifies the potential applications of the disclosed compounds in treating conditions such as lymphoma, endometriosis, psoriasis, lupus erythematosus, multiple sclerosis, and rheumatoid arthritis, including specific subtypes of lymphoma like primary central nervous system lymphoma or diffuse large B-cell lymphoma with MYD88 L265P mutation. Overall, the patent provides a comprehensive framework for utilizing the disclosed compound in therapeutic interventions targeting IRAK4 kinase activity for various medical conditions.
To know more about GlobalData’s detailed insights on Zhejiang Hisun Pharmaceutical, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
